About the study

This is a Phase I/IIa study designed to evaluate if experimental anti-PD-1 and anti-TIM-3 bispecific antibody, AZD7789 is safe, tolerable and efficacious in participants with advanced solid tumors.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

1. Must be ≥ 18 years of age
2. Histologically or cytologically documented Stage IIIB to IV non-small cell lung carcinoma (NSCLC) not amenable to curative surgery or radiation
3. Must have at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
4. Provision of archival or fresh tumor tissue sample and/or consent to undergo mandatory on-treatment biopsy for participants enrolled in Part A Dose-escalation
5. Provision of archival tumor tissue sample or fresh tissue sample for Part B Dose-expansion participants
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
7. Non-pregnant women and willingness of female participants to avoid pregnancy or male participants willing to avoid fathering children through highly effective methods of contraception
8. Adequate organ and bone marrow function measured within 28 days prior to first dose Part A Dose Escalation Additional

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.